
    
      Exacerbation in cystic fibrosis play an important role in terms of mortality and morbidity.
      Exacerbation frequencies is relatedto FEV1 decline and mortality. There is a relationship
      between exacerbation frequency and QoLdeterioration. Moreover exacerbation treatments present
      health costs burden leading to important physical psychological and social impact. Preventing
      exacerbation and early detection of these exacerbations may decrease intensity and freqauency
      of exacerbation leading to increase clinical status and QoLwith a decreased health cost.
    
  